Ross手术后再次手术的结局
本研究回顾性分析了1994年至2019年间在专门Ross中心接受Ross手术的225例连续患者,比较需再次手术与无需再次手术患者的特征与结局。66例(29.3%)需Ross相关再次手术,再次手术 operative mortality 为1.5%(1/66),15年生存率在需再次手术与无需再次手术患者间相似(91.2% vs 93.9%;P = .23)。结论认为在有经验的中心,Ross再次干预可安全实施并维持患者由初次Ross手术恢复的正常预期寿命至15年。
要点
- 225例Ross手术患者中66例(29.3%)需再次手术,再次手术 operative mortality 为1.5%(1/66)。
- 自体移植再次干预平均时间11 ± 6年,同种移植再次干预平均时间12 ± 7年。
- 15年生存率需再次手术组91.2% vs 无需再次手术组93.9%(P = .23),无显著差异。
核心结论
- 在有经验的中心,Ross再次干预可安全实施,并维持患者由初次Ross手术恢复的正常预期寿命至15年。
研究设计与样本
- 回顾性综述1994年至2019年间在专门Ross中心接受Ross手术的225例连续患者,比较有无再次手术患者的初次与再次手术特征及结局,采用多变量分析识别Ross相关再次干预的独立预测因素,Kaplan-Meier分析估计生存。
主要发现
- 66例(29.3%)需再次Ross手术,其中41例(18.2%)仅行自体移植再次手术,8例(3.6%)行同种移植再次干预,17例(7.6%)同时行自体移植和同种移植再次手术(12例为联合手术,5例为序贯手术)。
- 自体移植再次手术的平均时间为11 ± 6年,同种移植再次手术的平均时间为12 ± 7年。
- 需Ross相关再次干预的患者在初次Ross手术时更年轻(平均38 ± 11岁 vs 43 ± 11岁;P < .01),且纽约心脏协会III/IV级比例更高(56% vs 38%;P = .02)。
- 大多数行自体移植再次干预的患者有主动脉瓣关闭不全和/或动脉瘤(98.2%;57/58),同种移植再次干预的主要原因为肺动脉狭窄(92%;23/25)。
- Ross再次干预的 operative mortality 为1.5%(1/66),15年生存率在需再次手术与无需再次手术患者间相似(91.2% vs 93.9%;P = .23)。
临床怎么用
- 原文结论认为在有经验的中心,Ross再次干预可安全实施并维持患者由初次Ross手术恢复的正常预期寿命至15年。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Ross procedure is not commonly performed, owing to the procedural complexity and the risk of autograft and/or homograft reoperation. This study examined outcomes of patients undergoing Ross reinterventions at a dedicated Ross center. METHODS: We retrospectively reviewed 225 consecutive patients who underwent a Ross procedure between 1994 and 2019. Index and redo operation characteristics and outcomes were compared between patients with and those without redo operations. Multivariate analysis was used to identify independent predictors of Ross-related reinterventions. Survival was estimated with Kaplan-Meier analysis. RESULTS: Sixty-six patients (29.3%) required redo Ross surgery, 41 patients (18.2%) underwent autograft reoperation only, 8 patients (3.6%) had a homograft reintervention, and 17 patients (7.6%) had both autograft and homograft reoperations (12 as a combined procedure and 5 as sequential procedures). The mean time to reintervention was 11 ± 6 years for autograft reoperations and 12 ± 7 years for homograft reoperations. Patients who underwent Ross-related reinterventions were younger (mean, 38 ± 11 years vs 43 ± 11 years; P < .01) and had a higher rate of New York Heart Association class III/IV (56% vs 38%; P = .02) at the index Ross procedure. Most patients undergoing autograft reintervention had aortic insufficiency and/or aneurysm (98.2%; 57 of 58). The primary reason for homograft reintervention was pulmonary stenosis (92%; 23 of 25). The operative mortality of Ross reintervention was 1.5% (1 of 66). Survival at 15 years was similar in patients who required a redo operation and those who did not (91.2% vs 93.9%; P = .23). CONCLUSIONS: Ross reinterventions can be performed safely and maintain patients at the normal life expectancy restored by the index Ross procedure up to 15 years at experienced centers.
引用
- Shih E, Brinkman WT, Harrington KB, et al. Outcomes of redo operations after the Ross procedure. J Thorac Cardiovasc Surg. 2022. PMID: 36028359. doi:10.1016/j.jtcvs.2022.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。